Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Molecular cancer therapeutics - 1 Dec 2013

Lu Haibo, Wang Li, Gao Wen, Meng Jieru, Dai Bingbing, Wu Shuhong, Minna John, Roth Jack A, Hofstetter Wayne L, Swisher Stephen G, Fang Bingliang

Abstract excerpt

Insulin-like growth factor (IGF)-binding protein-2 (IGFBP2) expression is increased in various types of cancers, including in a subset of patients with lung cancer. Because IGFBP2 is involved in signal transduction of some critical cancer-related pathways, we analyzed the association between IGFBP2 and response to pathway-targeted agents in seven human non-small cell lung cancer (NSCLC) cell lines. Western blot...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodioxoles
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Protein-Tyrosine Kinases

Share to Inhibitory Concentration 50

Share to Pyrimidines

Share to Quinazolines

Share to Thiazoles

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24130049
DOI: 10.1158/1535-7163.MCT-13-0233
PMCID: PMC3858413

Genes

IGFBP2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.PMID 24130049Read ↗

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancerSemantic proximity Read ↗

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Semantic proximity Read ↗

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.Semantic proximity Read ↗

Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancerSemantic proximity Read ↗

Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.Semantic proximity Read ↗

Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsSemantic proximity Read ↗

Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signallingSemantic proximity Read ↗

PTK2-associated gene signature could predict the prognosis of IPFSemantic proximity Read ↗

Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.Semantic proximity Read ↗

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.Semantic proximity Read ↗

Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivoSemantic proximity Read ↗

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.